Retinal Disorder Treatment Market

Retinal Disorder Treatment Market by Types (Macular Degeneration [Dry Macular Degeneration and Wet Macular Degeneration], Diabetic Retinopathy, and Others), Dosage Form (Gels, Eye Solutions, Capsules & Tablets, Eye Drops, and Ointments), Distribution Channels (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-1866
  • Author: Growth Market Reports
  • Rating: 4.7
  • Total Reviews: 2
  • No. Of Pages: 210
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global retinal disorder treatment market size is projected to expand at a substantial CAGR during the forecast period, 2021-2028. The growth of the market is attributed to the increasing funding by regulatory bodies for researching ocular disorders.

Retinal Disorder Treatment Market Key Takeaways

According to the National Eye Institute, diabetic retinopathy may affect approximately 10 million and 14 million people in the US by 2030 and 2050, respectively. In 2017, NCBI published that the number of people with early and late age-related macular degeneration (AMD) in Europe is expected to be in between 14.9 and 21.5 million and between 3.9 and 4.8 million, respectively, by 2040. The data published in the World Population Prospects: 2019 Revision states that approximately one in 11 and one in four people in North America and Europe, respectively, will be aged 65 or older by 2050.

Market Trends, Drivers, Restraints, and Opportunities

  • Increasing prevalence of retinal disorders worldwide and requirement for effective and affordable treatment options are the key factors fueling the market growth
  • Growing geriatric population is expected to have a significant impact on the overall market.
  • The presence of strong pipeline products is expected to be one of the primary drivers driving the retinal disorder treatment market.
  • Rising adult and diabetic patient’s population across the globe is anticipated to drive the market growth during the forecast period.
  • High cost of retina treatment therapies and patient complaints are projected to hamper the market growth
  • Increasing R&D activities in developing countries is projected to fuel the market expansion in the coming years.

Scope of the Report

The report on the global retinal disorder treatment market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Retinal Disorder Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Types (Macular Degeneration [Dry Macular Degeneration, and Wet Macular Degeneration], Diabetic Retinopathy, and Others), Dosage Forms (Gels, Eye Solutions, Capsules & Tablets, Eye Drops, and Ointments), Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Santen Pharmaceutical Co., Ltd., REGENERON, Graybug Vision, Inc., Shire (Takeda Pharmaceuticals), Bayer AG, Genentech, Inc., Acucela Inc., and Pfizer Inc.

Retinal Disorder Treatment Market Segment Insights

Macular Degeneration segment is projected to account for a key market share

Based on types, the market is divided into macular degeneration, diabetic retinopathy, and others. The macular degeneration is further divided into dry macular degeneration and wet macular degeneration. The macular degeneration segment is expected to account for a key market share during the forecast period owing to the introduction of innovative products for the treatment of macular degeneration. Additionally, rising awareness of this type of retinal disorder is expected to drive the market growth during the forecast period. For instance, in February 2019, Bausch & Lomb announced the launch of SightMatters.com, a new educational online resource for people with age-related macular degeneration. According to the International Agency for the Prevention of Blindness, AMD is expected to affect approximately 196 million people worldwide by 2020.

Eye drop segment is expected to grow at a rapid pace

On the basis of dosage forms, the retinal disorder treatment market is segmented into gels, eye solutions, capsules & tablets, eye drops, and ointments. The eye solutions segment is expected to account for a significant market share during the forecast period. Several eye injections, such as Lucentis and EYLEA, are available for the treatment of retinal diseases. However, the eye drop segment is anticipated to expand at a rapid pace during the forecast period owing to cost-effectiveness and growing number of programs to create new AMD eye drops. For instance, in March 2018, PanOptica reported that it is undergoing phase 2/3 clinical trials for PAN-90806, a topically applied eye drops for the treatment of wet AMD.

Retinal Disorder Treatment Market By Dosage Forms

Online Pharmacy segment is anticipated to register a high CAGR

In terms of distribution channels, the retinal disorder treatment market is segregated into hospital pharmacies, online pharmacies, and retail pharmacies. The hospital pharmacies segment is expected to exhibit a high CAGR during the forecast period owing to the presence of high-quality treatment and value-based care to a large pool of patients. Apart from that, this segment is being driven by improving healthcare plans and favourable reimbursement policies. Growing investments in healthcare infrastructure in developing and underdeveloped economies is fueling the segment growth.

The online pharmacy segment is anticipated to expand at a rapid pace during the forecast period owing to increasing patient awareness about the advantages of online pharmacy, such as lower prices, convenience, and expert advice and counselling, among patients with retinal problems. According to a 2017 survey performed by the Alliance for Safe Online Pharmacies Global, 33% of survey participants acquired prescription medications from an online pharmacy in the US.

Retinal Disorder Treatment Market By Distribution Channels

North America is anticipated to dominate the market

On the basis of regions, the retinal disorder treatment market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the forecast period. The regional market growth is attributed to increasing prevalence of retinal disorders. According to study published on WebMD in 2019, AMD affects 25% of the general population in the US and more than 10% of the population aged between 65 and 74 years. However, the market in Asia Pacific is expected to exhibit a robust CAGR during the forecast period owing to high unmet clinical demands, the availability of effective treatment modalities, rising disposable income, and increasing awareness about early diagnosis in emerging countries.

Segments

Segments Covered in the Report
The global retinal disorder treatment market has been segmented on the basis of

Types
  • Macular Degeneration
    • Dry Macular Degeneration
    • Wet Macular Degeneration
  • Diabetic Retinopathy
  • Others
Dosage Forms
  • Gels
  • Eye Solutions
  • Capsules & Tablets
  • Eye Drops
  • Ointments
Distribution Channels
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • Santen Pharmaceutical Co., Ltd.
  • REGENERON
  • Graybug Vision, Inc.
  • Shire (Takeda Pharmaceuticals)
  • Bayer AG
  • Genentech, Inc.
  • Acucela Inc.
  • Pfizer Inc.

Competitive Landscape

Key players competing in the retinal disorder treatment market include Santen Pharmaceutical Co., Ltd., REGENERON, Graybug Vision, Inc., Shire (Takeda Pharmaceuticals), Bayer AG, Genentech, Inc., Acucela Inc., and Pfizer Inc.

Leading competitors in the market for retinal problem therapy use a variety of strategies to leverage their market position, such as increased R&D activities, product launches, partnerships, and collaborations. For instance, in July 2017, Santen Pharmaceutical Co., announced that it has initiated the development of DE-122 for the treatment of wet age-related macular degeneration, which is undergoing a Phase 2A clinical study in the US.

In 2017, Graybug Vision, Inc., began a phase 1/ 2 trial of GB-102 in 2017 for the treatment of wet AMD. This medication is a new sunitinib malate intravitreal injectable depot formulation. The launch of new drugs is expected to help the companies to expand their market share.

In May 2019, REGENERON got FDA clearance for Eylea (aflibercept) injection to treat all phases of diabetic retinopathy, lowering the chance of patients becoming blind. Such approvals are bound to boost the market significantly.

Technological developments and growing strategic collaborations are anticipated to foster the market growth. For instance, in October 2018, Ophthotech Corporation (IVERIC bio) announced a collaboration with the University of Florida Research Foundation and the University of Pennsylvania to develop and market an adeno-associated virus (AAV) gene therapy product for the treatment of best vitelliform macular fystrophy (BVMD).

Retinal Disorder Treatment Market By Key Players

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Retinal Disorder Treatment Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Retinal Disorder Treatment Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Retinal Disorder Treatment Market - Supply Chain
  4.5. Global Retinal Disorder Treatment Market Forecast
     4.5.1. Retinal Disorder Treatment Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Retinal Disorder Treatment Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Retinal Disorder Treatment Market Absolute $ Opportunity
5. Global Retinal Disorder Treatment Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Retinal Disorder Treatment Market Size and Volume Forecast by Types
     5.3.1. Macular Degeneration Diabetic Retinopathy Others
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Retinal Disorder Treatment Market Analysis and Forecast by Region
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Region
     6.2.2. Y-o-Y Growth Projections by Region
  6.3. Retinal Disorder Treatment Market Size and Volume Forecast by Region
     6.3.1. North America
     6.3.2. Latin America
     6.3.3. Europe
     6.3.4. Asia Pacific
     6.3.5. Middle East and Africa (MEA)
  6.4. Absolute $ Opportunity Assessment by Region
  6.5. Market Attractiveness/Growth Potential Analysis by Region
  6.6. Global Retinal Disorder Treatment Demand Share Forecast, 2019-2026
7. North America Retinal Disorder Treatment Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
  7.2. North America Retinal Disorder Treatment Market Size and Volume Forecast by Country
     7.2.1. U.S.
     7.2.2. Canada
  7.3. Absolute $ Opportunity Assessment by Country
  7.4. North America Retinal Disorder Treatment Market Size and Volume Forecast by Types
     7.4.1. Macular Degeneration Diabetic Retinopathy Others
  7.5. Basis Point Share (BPS) Analysis by Types
  7.6. Y-o-Y Growth Projections by Types
  7.7. Market Attractiveness/Growth Potential Analysis
     7.7.1. By Country
     7.7.2. By Product Type
     7.7.3. By Application
  7.8. North America Retinal Disorder Treatment Demand Share Forecast, 2019-2026
8. Latin America Retinal Disorder Treatment Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Latin America Average Pricing Analysis
  8.2. Latin America Retinal Disorder Treatment Market Size and Volume Forecast by Country
      8.2.1. Brazil
      8.2.2. Mexico
      8.2.3. Rest of Latin America
   8.3. Absolute $ Opportunity Assessment by Country
  8.4. Latin America Retinal Disorder Treatment Market Size and Volume Forecast by Types
     8.4.1. Macular Degeneration Diabetic Retinopathy Others
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. Market Attractiveness/Growth Potential Analysis
     8.7.1. By Country
     8.7.2. By Product Type
     8.7.3. By Application
  8.8. Latin America Retinal Disorder Treatment Demand Share Forecast, 2019-2026
9. Europe Retinal Disorder Treatment Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Europe Average Pricing Analysis
  9.2. Europe Retinal Disorder Treatment Market Size and Volume Forecast by Country
     9.2.1. Germany
     9.2.2. France
     9.2.3. Italy
     9.2.4. U.K.
     9.2.5. Spain
     9.2.6. Russia
     9.2.7. Rest of Europe
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Europe Retinal Disorder Treatment Market Size and Volume Forecast by Types
     9.4.1. Macular Degeneration Diabetic Retinopathy Others
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Market Attractiveness/Growth Potential Analysis
     9.7.1. By Country
     9.7.2. By Product Type
     9.7.3. By Application
  9.8. Europe Retinal Disorder Treatment Demand Share Forecast, 2019-2026
10. Asia Pacific Retinal Disorder Treatment Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Asia Pacific Average Pricing Analysis
  10.2. Asia Pacific Retinal Disorder Treatment Market Size and Volume Forecast by Country
     10.2.1. China
     10.2.2. Japan
     10.2.3. South Korea
     10.2.4. India
     10.2.5. Australia
     10.2.6. Rest of Asia Pacific (APAC)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Asia Pacific Retinal Disorder Treatment Market Size and Volume Forecast by Types
     10.4.1. Macular Degeneration Diabetic Retinopathy Others
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Market Attractiveness/Growth Potential Analysis
     10.7.1. By Country
     10.7.2. By Product Type
     10.7.3. By Application
  10.8. Asia Pacific Retinal Disorder Treatment Demand Share Forecast, 2019-2026
11. Middle East & Africa Retinal Disorder Treatment Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Middle East & Africa Average Pricing Analysis
  11.2. Middle East & Africa Retinal Disorder Treatment Market Size and Volume Forecast by Country
     11.2.1. Saudi Arabia
     11.2.2. South Africa
     11.2.3. UAE
     11.2.4. Rest of Middle East & Africa (MEA)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Middle East & Africa Retinal Disorder Treatment Market Size and Volume Forecast by Types
     11.4.1. Macular Degeneration Diabetic Retinopathy Others
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Market Attractiveness/Growth Potential Analysis
     11.7.1. By Country
     11.7.2. By Product Type
     11.7.3. By Application
  11.8. Middle East & Africa Retinal Disorder Treatment Demand Share Forecast, 2019-2026
12. Competition Landscape
  12.1. Global Retinal Disorder Treatment Market: Market Share Analysis
  12.2. Retinal Disorder Treatment Distributors and Customers
  12.3. Retinal Disorder Treatment Market: Competitive Dashboard
  12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     12.4.1. Santen Pharmaceutical Co., Ltd. REGENERON Graybug Vision, Inc. Shire (Takeda Pharmaceuticals) Bayer AG Genentech, Inc.  
Segments Covered in the Report
The global retinal disorder treatment market has been segmented on the basis of

Types
  • Macular Degeneration
    • Dry Macular Degeneration
    • Wet Macular Degeneration
  • Diabetic Retinopathy
  • Others
Dosage Forms
  • Gels
  • Eye Solutions
  • Capsules & Tablets
  • Eye Drops
  • Ointments
Distribution Channels
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • Santen Pharmaceutical Co., Ltd.
  • REGENERON
  • Graybug Vision, Inc.
  • Shire (Takeda Pharmaceuticals)
  • Bayer AG
  • Genentech, Inc.
  • Acucela Inc.
  • Pfizer Inc.

Key players competing in the retinal disorder treatment market include Santen Pharmaceutical Co., Ltd., REGENERON, Graybug Vision, Inc., Shire (Takeda Pharmaceuticals), Bayer AG, Genentech, Inc., Acucela Inc., and Pfizer Inc.

Leading competitors in the market for retinal problem therapy use a variety of strategies to leverage their market position, such as increased R&D activities, product launches, partnerships, and collaborations. For instance, in July 2017, Santen Pharmaceutical Co., announced that it has initiated the development of DE-122 for the treatment of wet age-related macular degeneration, which is undergoing a Phase 2A clinical study in the US.

In 2017, Graybug Vision, Inc., began a phase 1/ 2 trial of GB-102 in 2017 for the treatment of wet AMD. This medication is a new sunitinib malate intravitreal injectable depot formulation. The launch of new drugs is expected to help the companies to expand their market share.

In May 2019, REGENERON got FDA clearance for Eylea (aflibercept) injection to treat all phases of diabetic retinopathy, lowering the chance of patients becoming blind. Such approvals are bound to boost the market significantly.

Technological developments and growing strategic collaborations are anticipated to foster the market growth. For instance, in October 2018, Ophthotech Corporation (IVERIC bio) announced a collaboration with the University of Florida Research Foundation and the University of Pennsylvania to develop and market an adeno-associated virus (AAV) gene therapy product for the treatment of best vitelliform macular fystrophy (BVMD).

Retinal Disorder Treatment Market By Key Players

Buy Report